References
- Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023;82:3–18.
- Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3. Arthritis Rheumatol 2021;73:e1–12.
- World Health Organization. WHO coronavirus (COVID-19) dashboard. [cited 2023 Sep 26]. Available from: https://covid19.who.int/.
- Alzahrani OR, Alanazi AD, Hawsawi YM, Alatwi HE, Alharbi AA. Gastrointestinal manifestations of COVID-19: an updated systematic review. Trop Biomed 2022;39:428–33.
- Al Argan RJ, Alqatari SG, Al Said AH, Alsulaiman RM, Noor A, Al Sheekh LA, et al. Gastrointestinal perforation secondary to COVID-19: case reports and literature review. Medicine (Baltimore) 2021;100:e25771.
- Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 2017;76:504–10.
- Monemi S, Berber E, Sarsour K, Wang J, Lampl K, Bharucha K, et al. Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources. Rheumatol Ther 2016;3:337–52.
- Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or Abatacept. Rheumatology (Oxford) 2022;61:953–62.
- Saad E, Awadelkarim A, Agab M, Babkir A. Tocilizumab-associated small bowel perforation in a young patient with rheumatoid arthritis: a lesson to remember during COVID-19 pandemic. J Med Cases 2022;13:135–9.